Commercial Opportunities

RegeneRx has designed each formulation to serve a number of target disease indications within a broad area of interest. Each indication is supported by patents and research data, much of which have been published in peer-reviewed scientific and medical journals. Although RegeneRx cannot pursue all of these indications, partners have an opportunity to optimize indications that are important to their own therapeutic area of focus. 

PRODUCT CANDIDATE

TARGET INDICATION

APPROXIMATE U.S.
POPULATION/YEAR*
RGN-259
(Tβ4 Eye Drop)
Dry Eye Syndrome
Neurotrophic Keratopathy (orphan) 
Recurrent Corneal Erosions
Corneal Surgeries
20M
~10K**
2.8M
1.3M
RGN-352
(Tβ4 Injectable Solution)
Acute Myocardial Infarction (AMI)
Peripheral Neuropathy
Stroke
Traumatic Brain Injury (TBI)
Multiple Sclerosis
650K
15M
700K
500K
300K
RGN-137
(Tβ4 dermal gel)
Epidermolysis Bullosa (EB)
Pressure and Venous Stasis Ulcers
Scarring and Burns
12K
>3M
TBD


 

*Company estimates
**Stage 2 & 3, based on EU prevalence data and Clin Ophthalmol. 2014; 8: 571–579.


print email